Figure 4 depicts the growth of in-hospital, off-label vs. on-label
uses of rFVIIa in Premier database from 2000-2008. It examines the following
hospitalizations: hemophilia, ICH, trauma, CV surgery and all other
off-label use. It shows how over time cases of use for hemophilia increased
3.7 fold since 2000 but then plateaued; how CV surgery was the most frequent
and most rapidly rising indication, although the frequency level may be
leveling off; how use of rFVIIa for trauma grew continuously between 2002
and 2007 but leveled off in 2008; and how ICH reached sizable scale only in
2005, growing rapidly until 2008. Figures 3 and 4 present similar
information. However, “all other” in Figure 4 includes liver transplantation
and prostatectomy, as well as all of the other indications.

Figure 4Growth of in-hospital, off-label vs. on-label uses of rFVIIa in Premier database, 2000–2008

Figures 3 and 4 present similar information. However, “all other” in Figure 4 includes liver transplantation and prostatectomy, as well as all of the other indications.

From: Results

Cover of Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet].
Comparative Effectiveness Reviews, No. 21.
Yank V, Tuohy CV, Logan AC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.